{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:35:22Z","timestamp":1763350522766,"version":"3.45.0"},"reference-count":0,"publisher":"Journal of Biological Methods","issue":"4","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bladder"],"abstract":"<jats:p>Background: T1 high-grade (T1HG) bladder cancer (BC) carries substantial risks of recurrence and progression, deserving of heightened clinical attention. Objective: The present study evaluated the management approaches and reported 14-year real-world outcomes in patients with T1HG BC from a single-center cohort. Methods: Data were retrospectively collected from primary T1HG patients who had undergone transurethral resection of bladder tumors (TURBT) at our institution between 2010 and 2023. A total of 165 patients were included. Their baseline characteristics, pathological findings, adjuvant therapies, recurrence, progression, and survival outcomes were analyzed. Predictors of tumor recurrence were modeled using multivariable analyses. Results: Tumor recurrence was significantly associated with post-operative Bacillus Calmette&amp;ndash;Gu&amp;eacute;rin (BCG) treatment (odds ratio [OR]: 0.315, p=0.001) and tumor multifocality (OR: 0.476, p=0.033). Among patients having received post-operative BCG treatment, tumor recurrence bore a significant correlation with tumor multifocality (OR: 0.328, p=0.027), and elevated body mass index (BMI) was identified as a potential accelerator of recurrence (hazard ratio: 1.098, p=0.01). The 10-year recurrence-free survival rate among all patients stood at 54.9% (95% confidence interval [CI]: 44.3&amp;ndash;65.5%), with a median of 134 months (95% CI: 64.7&amp;ndash;203.3 months). The rate of re-TURBT was 20%. The 10-year progression-free survival was 87.2% (95% CI: 81.0&amp;ndash;93.5%) and the 10-year overall survival was 66.7% (95% CI: 54.0&amp;ndash;79.4%). The 10-year cancer-specific survival and the 10-year cystectomy-free survival (CFS) rates were 93.7% (95% CI: 88.4&amp;ndash;99.0%) and 86.3% (95% CI: 79.8&amp;ndash;92.8%), respectively. Notably, BCG treatment significantly improved CFS (p=0.01). Conclusion: Recurrence in T1HG disease is associated with BCG therapy and tumor multifocality, with a high BMI potentially promoting relapse.<\/jats:p>","DOI":"10.14440\/bladder.0039","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T09:40:26Z","timestamp":1755855626000},"page":"e21200060","source":"Crossref","is-referenced-by-count":0,"title":["Real-world management of T1 high-grade bladder cancer: A 14-year retrospective single-center study"],"prefix":"10.14440","volume":"12","author":[{"given":"Zexuan","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5574","published-online":{"date-parts":[[2025,8,22]]},"container-title":["Bladder"],"original-title":[],"link":[{"URL":"https:\/\/web-api.polscientific.com\/uploads\/file\/asp\/20251113155107807e21978.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/web-api.polscientific.com\/uploads\/file\/asp\/20251113155107807e21978.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:29:31Z","timestamp":1763350171000},"score":1,"resource":{"primary":{"URL":"https:\/\/polscientific.com\/journal\/Bladder\/12\/4\/10.14440\/bladder.0039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,13]]}},"URL":"https:\/\/doi.org\/10.14440\/bladder.0039","relation":{},"ISSN":["2327-2120"],"issn-type":[{"type":"electronic","value":"2327-2120"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}